Is buspirone (Buspar) appropriate for treating self‑injurious biting in a patient with anxiety and depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Buspirone for Self-Injurious Biting: Limited Evidence but May Be Appropriate

Buspirone may be appropriate for treating self-injurious biting behavior in patients with anxiety and depression, though the evidence is limited to small open-label studies showing mixed but generally favorable responses, with reductions in self-injury ranging from 13% to 72%. 1

Evidence for Self-Injurious Behavior

The most relevant evidence comes from a 1994 study examining buspirone specifically for intractable self-injury in five adults with mental retardation 1. Key findings:

  • All five individuals showed some response, with self-injury reductions of 13-72% depending on dose
  • Most effective doses were 30 mg/day (three patients) or 52.5 mg/day (two patients)
  • Buspirone was used alone in two patients and as adjunct to thioridazine in three
  • Importantly, coexisting anxiety symptoms did not predict favorable response to buspirone
  • Patients were maintained on effective doses for 6-33 weeks

An earlier 1989 case series reported that 9 of 14 developmentally disabled individuals with anxiety, aggression, and self-injurious behaviors responded favorably to buspirone 2.

Critical Caveat: Risk of Behavioral Worsening

A major pitfall to avoid: In a 1997 study of prepubertal children with anxiety and moderate aggression, buspirone was discontinued in 25% of patients—4 developed increased aggression and agitation, and 2 developed euphoric mania 3. This suggests buspirone may pose behavioral risks in approximately one-quarter of patients with aggressive/self-injurious behaviors.

FDA-Approved Indication and Mechanism

Buspirone is FDA-approved for generalized anxiety disorder, not self-injurious behavior 4. It works as a partial agonist at serotonin 5-HT1A receptors and antagonist at dopamine D2 receptors 5. The FDA label specifically states it has no established antipsychotic activity and should not replace appropriate antipsychotic treatment when needed 4.

Evidence for Anxiety and Depression

For the patient's comorbid anxiety and depression, buspirone has stronger evidence:

  • Anxiety: Buspirone is FDA-approved for generalized anxiety disorder and has demonstrated efficacy in controlled trials 4. Recent 2025 data shows adjunctive buspirone with antidepressants reduced anxiety scores from 25.2 to 15.4 over 12 weeks, with 39.1% response rate 6

  • Depression: A 1990 controlled study showed 70% of buspirone-treated patients with major depression and anxiety were moderately or markedly improved versus 35% on placebo 7. The 2025 study also showed depression scores improved significantly (19.4 to 12.7) 6

Clinical Recommendation Algorithm

For this patient with anxiety, depression, AND self-injurious biting:

  1. Start buspirone at 15 mg/day divided into 2-3 doses, titrating up to 30-45 mg/day over 2-3 weeks based on response 4, 1

  2. Monitor closely in first 2-4 weeks for paradoxical worsening of aggression or agitation (occurs in ~25% of cases) 3

  3. If behavioral worsening occurs, discontinue immediately and consider alternative treatments (SSRIs, antipsychotics, or behavioral interventions)

  4. If tolerated, assess response at 4-6 weeks: Look for reduction in self-injury frequency, anxiety symptoms (HAMA scale), and depression symptoms (HAMD scale)

  5. Effective doses typically range 30-52.5 mg/day for self-injury, though anxiety may respond to lower doses 1

  6. Continue for at least 6-8 weeks if showing partial response, as full effects may take time 4, 6

Important Safety Considerations

  • Do not combine with MAOIs due to risk of hypertensive crisis 4
  • Monitor for serotonin syndrome if combined with other serotonergic agents (SSRIs, SNRIs) 4
  • Buspirone may cause dizziness, particularly early in treatment 8
  • The drug is well-tolerated with only 3.7% adverse event rate in recent studies 6

Bottom Line

While buspirone is not FDA-approved for self-injurious behavior and evidence is limited to small open-label studies, it represents a reasonable trial given its established efficacy for the patient's anxiety and depression, favorable safety profile, and documented cases of reducing self-injury by 13-72%. The key is close monitoring for paradoxical behavioral worsening in the first month, which occurs in approximately one-quarter of patients with aggressive behaviors. If this occurs, discontinue immediately and pursue alternative treatments.

References

Research

Clinical effects of buspirone on intractable self-injury in adults with mental retardation.

Journal of the American Academy of Child and Adolescent Psychiatry, 1994

Research

Buspirone: what is it all about?

Brain research, 2012

Research

Effectiveness of Buspirone in Alleviating Anxiety Symptoms in Patients with Depressive Disorder: A Multicenter Prospective Observational Study in Korea.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2025

Research

Buspirone in depressed outpatients: a controlled study.

Psychopharmacology bulletin, 1990

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.